Dengue vaccines: Recent developments, ongoing challenges and current candidates

Expert Review of Vaccines

Volumn 12, Issue 8, 2013, Pages 933-953

  McArthur, Monica A ^a   Sztein, Marcelo B ^a   Edelman, Robert ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

antibody dependent enhancement; dengue fever; dengue hemorrhagic fever; dengue virus; immunopathogenesis; vaccine

Indexed keywords

DENGUE VACCINE;

ARBOVIRUS; DENGUE; DRUG RESPONSE; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; VACCINATION; VECTOR CONTROL;

ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DRUG DISCOVERY; HUMANS;

EID: 84887710272     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.815412     Document Type: Review

References (149)

1. Beatty ME, Beutels P, Meltzer MI et al. Health economics of dengue: A systematic literature review and expert panel's assessment. Am. J. Trop. Med. Hyg. 84(3), 473-488 (2011
2. Gubler DJ. The global emergence/ resurgence of arboviral diseases as public health problems. Arch. Med. Res. 33(4), 330-342 (2002
3. Scientific Working Group on Dengue. Report of the Scientific Working Group on Dengue, 1-5 October 2006. 31, 183-186 (2007
4. World Health Organization. Sustaining the drive to overcome the global impact of neglected tropical diseases. Second WHO report on neglected tropical diseases World Helath Organization, Geneva, Switzerland (2013
5. World Health Organization. Dengue and severe dengue. World Helath Organization, Geneva, Switzerland (2012
6. Bhatt S, Gething PW, Brady OJ et al. The global distribution and burden of dengue. Nature 496(7446), 504-507 (2013
7. Gubler DJ. The economic burden of dengue. Am. J. Trop. Med. Hyg. 86(5), 743-744 (2012
8. Halasa YA, Shepard DS, Zeng W. Economic cost of dengue in Puerto Rico. Am. J. Trop. Med. Hyg. 86(5), 745-752 (2012
9. Halstead SB. Dengue. Lancet 370(9599), 1644-1652 (2007
10. Whitehorn J, Farrar J. Dengue. Br. Med. Bull. 95, 161-173 (2010
11. Lindenbach BD, Rice CM. Molecular biology of flaviviruses. Adv. Virus Res. 59, 23-61 (2003
12. Heinz FX, Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine 30(29), 4301-4306 (2012
13. Kanai R, Kar K, Anthony K et al. Crystal structure of west Nile virus envelope glycoprotein reveals viral surface epitopes. J. Virol. 80(22), 11000-11008 (2006
14. Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. USA. 100(12), 6986-6991 (2003
15. Modis Y, Ogata S, Clements D, Harrison SC. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J. Virol. 79(2), 1223-1231 (2005
16. Nybakken GE, Nelson CA, Chen BR, Diamond MS, Fremont DH. Crystal structure of the West Nile virus envelope glycoprotein. J. Virol. 80(23), 11467-11474 (2006
17. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375(6529), 291-298 (1995
18. Zhang Y, Zhang W, Ogata S et al. Conformational changes of the flavivirus E glycoprotein. Structure 12(9), 1607-1618 (2004
19. Heinz FX, Allison SL. Flavivirus structure and membrane fusion. Adv. Virus Res. 59, 63-97 (2003
20. Wahala WM, Silva AM. The human antibody response to dengue virus infection. Viruses 3(12), 2374-2395 (2011
21. WHO. Dengue Guidelines for Diagnosis, Treatment, Prevention, and Control. World Helath Organization, Geneva, Switzerland (2009
22. WHO. Dengue Hemorrhagic Fever: Diagnosis, treatment, prevention, and Control. (1997
23. Narvaez F, Gutierrez G, Perez MA et al. Evaluation of the traditional and revised WHO classifications of Dengue disease severity. PLoS Negl. Trop. Dis. 5(11), e1397 (2011
24. Were F. The dengue situation in Africa. Paediatr. Int. Child Health 32(Suppl. 1), 18-21 (2012
25. WHO. Working to Overcome the Global Impact of Neglected Tropical Diseases. First WHO Report on Neglected Tropical Diseases, Geneva, Switzerland (2010
26. Lambrechts L, Scott TW, Gubler DJ. Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission. PLoS Negl. Trop. Dis. 4(5), e646 (2010
27. Gubler DJ. Dengue, urbanization and globalization: The Unholy Trinity of the 21(st) century. Trop. Med. Health 39(Suppl. 4), 3-11 (2011
28. Tantawichien T. Dengue fever and dengue haemorrhagic fever in adolescents and adults. Paediatr. Int. Child Health 32(Suppl. 1), 22-27 (2012
29. Cardoso IM, Cabidelle Ade S, Borges Pde C et al. Dengue: Clinical forms and risk groups in a high incidence city in the southeastern region of Brazil. Rev. Soc. Bras. Med. Trop. 44(4), 430-435 (2011
30. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 10(2), 100-103 (2002
31. Tapia-Conyer R, Betancourt-Cravioto M, Mendez-Galván J. Dengue: An escalating public health problem in Latin America. Paediatr. Int. Child Health 32(Suppl. 1), 14-17 (2012
32. Blanton RE, Silva LK, Morato VG et al. Genetic ancestry and income are associated with dengue hemorrhagic fever in a highly admixed population. Eur. J. Hum. Genet. 16(6), 762-765 (2008
33. Halstead SB, Streit TG, Lafontant JG et al. Haiti: Absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am. J. Trop. Med. Hyg. 65(3), 180-183 (2001
34. Racloz V, Ramsey R, Tong S, Hu W. Surveillance of dengue fever virus: A review of epidemiological models and early warning systems. PLoS Negl. Trop. Dis. 6(5), e1648 (2012
35. Banu S, Hu W, Hurst C, Tong S. Dengue transmission in the Asia-Pacific region: Impact of climate change and socio-environmental factors. Trop. Med. Int. Health 16(5), 598-607 (2011
36. Alvarez M, Pavon-Oro A, Rodriguez-Roche R et al. Neutralizing antibody response variation against dengue 3 strains. J. Med. Virol. 80(10), 1783-1789 (2008
37. Sabin AB, Schlesinger RW. Production of immunity to Dengue with virus modified by propagation in mice. Science 101(2634), 640-642 (1945
38. Halstead SB. Pathogenesis of dengue: Challenges to molecular biology. Science 239(4839), 476-481 (1988
39. Thein S, Aung MM, Shwe TN et al. Risk factors in dengue shock syndrome. Am. J. Trop. Med. Hyg. 56(5), 566-572 (1997
40. Halstead SB. Antibodies determine virulence in dengue. Ann. NY Acad. Sci. 117(Suppl. 1), E48-E56 (2009
41. Vaughn DW, Green S, Kalayanarooj S et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181(1), 2-9 (2000
42. Pang T, Cardosa MJ, Guzman MG. Of cascades and perfect storms: The immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol. Cell Biol. 85(1), 43-45 (2007
43. Rothman AL. T lymphocyte responses to heterologous secondary dengue virus infections. Ann. NY. Acad. Sci. 117( Suppl. 1), E36-E41 (2009
44. Halstead SB. Neutralization and antibodydependent enhancement of dengue viruses. Adv. Virus Res. 60, 421-467 (2003
45. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: Implications for vaccine development. Cell Host Microbe 4(3), 229-238 (2008
46. Avirutnan P, Punyadee N, Noisakran S et al. Vascular leakage in severe dengue virus infections: A potential role for the nonstructural viral protein NS1 and complement. J. Infect. Dis. 193(8), 1078-1088 (2006
47. Malasit P. Complement and dengue haemorrhagic fever/shock syndrome. Southeast Asian J. Trop. Med. Public Health 18(3), 316-320 (1987
48. Dowd KA, Pierson TC. Antibody-mediated neutralization of flaviviruses: A reductionist view. Virology 411(2), 306-315 (2011
49. Chau TN, Quyen NT, Thuy TT et al. Dengue in Vietnamese infants-results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J. Infect. Dis. 198(4), 516-524 (2008
50. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40(4), 444-451 (1989
51. Moi ML, Lim CK, Takasaki T, Kurane I. Involvement of the Fc gamma receptor IIA cytoplasmic domain in antibody-dependent enhancement of dengue virus infection. J. Gen. Virol. 91(Pt 1), 103-111 (2010
52. Laoprasopwattana K, Libraty DH, Endy TP et al. Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J. Infect. Dis. 192(3), 510-519 (2005
53. Libraty DH, Acosta LP, Tallo V et al. A prospective nested case-control study of Dengue in infants: Rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 6(10), e1000171 (2009
54. Rothman AL. Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr. Top. Microbiol. Immunol. 338, 83-98 (2010
55. Butthep P, Chunhakan S, Yoksan S, Tangnararatchakit K, Chuansumrit A. Alteration of Cytokines and Chemokines during Febrile Episodes Associated with Endothelial cell Damage and Plasma Leakage in Dengue Hemorrhagic Fever. Pediatr. Infect. Dis. J. 31(12), e232-e238 (2012
56. Gunther VJ, Putnak R, Eckels KH et al. A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine 29(22), 3895-3904 (2011
57. Mangada MM, Endy TP, Nisalak A et al. Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. J. Infect. Dis. 185(12), 1697-1703 (2002
58. Mongkolsapaya J, Dejnirattisai W, Xu XN et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9(7), 921-927 (2003
59. Bossi F, Fischetti F, Pellis V et al. Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex. J. Immunol. 173(11), 6921-6927 (2004
60. De Alwis R, Smith SA, Olivarez NP et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl Acad. Sci. USA 109(19), 7439-7444 (2012
61. Teoh EP, Kukkaro P, Teo EW et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci. Transl. Med. 4(139), 139ra183 (2012
62. Endy TP, Nisalak A, Chunsuttitwat S et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis. 189(6), 990-1000 (2004
63. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 21(2), 123-132 (2008
64. Rodrigo WW, Alcena DC, Rose RC, Jin X, Schlesinger JJ. An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells. Am. J. Trop. Med. Hyg. 80(1), 61-65 (2009
65. Moi ML, Lim CK, Chua KB, Takasaki T, Kurane I. Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcgR-expressing cells. PLoS Negl. Trop. Dis. 6(2), e1536 (2012
66. Sun W, Eckels KH, Putnak JR et al. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J. Infect. Dis. 207(5), (2013
67. Sabchareon A, Wallace D, Sirivichayakul C et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled Phase 2b trial. Lancet 380(9853), 1559-1567 (2012
68. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54(11), 1615-1617 (2012
69. Raviprakash K, Luke T, Doukas J et al. A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits. Hum. Vaccin. Immunother. 8(12), 1764-1768 (2012
70. Zompi S, Harris E. Animal models of dengue virus infection. Viruses 4(1), 62-82 (2012
71. Cassetti MC, Durbin A, Harris E et al. Report of an NIAID workshop on dengue animal models. Vaccine 28(26), 4229-4234 (2010
72. Atrasheuskaya A, Petzelbauer P, Fredeking TM, Ignatyev G. Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol. Med. Microbiol. 35(1), 33-42 (2003
73. Shresta S, Kyle JL, Robert Beatty P, Harris E. Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. Virology 319(2), 262-273 (2004
74. Solomon T, Dung NM, Vaughn DW et al. Neurological manifestations of dengue infection. Lancet 355(9209), 1053-1059 (2000
75. Chen HC, Hofman FM, Kung JT, Lin YD, Wu-Hsieh BA. Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage. J. Virol. 81(11), 5518-5526 (2007
76. Paes MV, Pinhao AT, Barreto DF et al. Liver injury and viremia in mice infected with dengue-2 virus. Virology 338(2), 236-246 (2005
77. Souza DG, Fagundes CT, Sousa LP et al. Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection. Proc. Natl Acad. Sci. USA 106(33), 14138-14143 (2009
78. Beaumier CM, Rothman AL. Cross-reactive memory CD4+ T cells alter the CD8+ T-cell response to heterologous secondary dengue virus infections in mice in a sequence-specific manner. Viral Immunol. 22(3), 215-219 (2009
79. White LJ, Parsons MM, Whitmore AC, Williams BM, De Silva A, Johnston RE. An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. J. Virol. 81(19), 10329-10339 (2007
80. An J, Zhou DS, Zhang JL, Morida H, Wang JL, Yasui K. Dengue-specific CD8+ T cells have both protective and pathogenic roles in dengue virus infection. Immunol. Lett. 95(2), 167-174 (2004
81. Blaney JE Jr, Johnson DH, Manipon GG et al. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 300(1), 125-139 (2002
82. Lin YL, Liao CL, Chen LK et al. Study of Dengue virus infection in SCID mice engrafted with human K562 cells. J. Virol. 72(12), 9729-9737 (1998
83. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80(20), 10208-10217 (2006
84. Williams KL, Zompi S, Beatty PR, Harris E. A mouse model for studying dengue virus pathogenesis and immune response. Ann. NY. Acad. Sci. 117(Suppl. 1), E12-E23 (2009
85. Akkina R. Human immune responses and potential for vaccine assessment in humanized mice. Curr. Opin. Immunol. 25(3), 403-409 (2013
86. Jaiswal S, Pazoles P, Woda M et al. Enhanced humoral and HLA-A2-restricted dengue virus-specific T-cell responses in humanized BLT NSG mice. Immunology 136(3), 334-343 (2012
87. Halstead SB, Shotwell H, Casals J. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J. Infect. Dis. 128(1), 7-14 (1973
88. Whitehead RH, Chaicumpa V, Olson LC, Russell PK. Sequential dengue virus infections in the white-handed gibbon (Hylobates lar). Am. J. Trop. Med. Hyg. 19(1), 94-102 (1970
89. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Monoclonal antibodymediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl Acad. Sci. USA 104(22), 9422-9427 (2007
90. Durbin AP, Karron RA, Sun W et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am. J. Trop. Med. Hyg. 65(5), 405-413 (2001
91. Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 29(42), 7242-7250 (2011
92. Durbin AP, McArthur J, Marron JA et al. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum. Vaccin. 2(4), 167-173 (2006
93. Durbin AP, Whitehead SS, McArthur J et al. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J. Infect. Dis. 191(5), 710-718 (2005
94. McArthur JH, Durbin AP, Marron JA et al. Phase I clinical evaluation of rDEN4Delta30- 200,201: A live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am. J. Trop. Med. Hyg. 79(5), 678-684 (2008
95. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to Phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29(42), 7229-7241 (2011
96. Osorio JE, Brewoo JN, Silengo SJ et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Am. J. Trop. Med. Hyg. 84(6), 978-987 (2011
97. Osorio JE, Huang CY, Kinney RM, Stinchcomb DT. Development of DENVax: A chimeric dengue-2 PDK-53- based tetravalent vaccine for protection against dengue fever. Vaccine 29(42), 7251-7260 (2011
98. Blanc G, Caminopetros J. Contribution a l'etude de la vaccination contre la dengue. Bulletin de l'Académie nationale de médecine 102(24), 1-4 (1929
99. Simmons J, St John J, Reynolds F. Experimental studies of dengue. Philippine J. Sci. 44, 1-252 (1931
100. McArthur MA, Holbrook MR. Japanese encephalitis vaccines. J. Bioterror. Biodef. S1, 2 (2011
101. Monath TP. Yellow fever: An update. Lancet Infect. Dis. 1(1), 11-20 (2001
102. Capeding RZ, Luna IA, Bomasang E et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled Phase I trial in the Philippines. Vaccine 29(22), 3863-3872 (2011
103. Durbin AP, Whitehead SS, Shaffer D, et al Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 29(42), 7242-7250 (2011
104. Lanata CF, Andrade T, Gil AI et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: Randomized, controlled, Phase II study in Piura, Peru. Vaccine 30(41), 5935-5941 (2012
105. Simasathien S, Thomas SJ, Watanaveeradej V et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am. J. Trop. Med. Hyg. 78(3), 426-433 (2008
106. Sun W, Cunningham D, Wasserman SS et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum. Vaccin. 5(1), 33-40 (2009
107. Watanaveeradej V, Simasathien S, Nisalak A et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. Am. J. Trop. Med. Hyg. 85(2), 341-351 (2011
108. Wright PF, Durbin AP, Whitehead SS et al. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. Am. J. Trop. Med. Hyg. 81(5), 834-841 (2009
109. Guirakhoo F, Arroyo J, Pugachev KV et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75(16), 7290-7304 (2001
110. Guirakhoo F, Weltzin R, Chambers TJ et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J. Virol. 74(12), 5477-5485 (2000
111. Qiao M, Shaw D, Forrat R, Wartel-Tram A, Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am. J. Trop. Med. Hyg. 85(4), 724-731 (2011
112. Sin Leo Y, Wilder-Smith A, Archuleta S et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. Hum. Vaccin. Immunother. 8(9), 1259-1271 (2012
113. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J. Infect. Dis. 201(3), 370-377 (2010
114. Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico city: Randomized controlled Phase 1 trial of safety and immunogenicity. Pediatr. Infect. Dis. J. doi:10.1097/INF.0b013e3181fe05af (2010) (Epub ahead of print
115. Edelman R, Wasserman SS, Bodison SA et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am. J. Trop. Med. Hyg. 69(Suppl. 6), 48-60 (2003
116. Thomas SJ, Eckels KH, Carletti I et al. A Phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am. J. Trop. Med. Hyg. 88(1), 73-88 (2013
117. Huang CY, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J. Virol. 77(21), 11436-11447 (2003
118. Brewoo JN, Kinney RM, Powell TD et al. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Vaccine 30(8), 1513-1520 (2012
119. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu. Rev. Immunol. 29, 587-619 (2011
120. Blaney JE Jr, Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am. J. Trop. Med. Hyg. 71(6), 811-821 (2004
121. Blaney JE Jr, Hanson CT, Hanley KA, Murphy BR, Whitehead SS. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect. Dis. 4, 39 (2004
122. Durbin AP, McArthur JH, Marron JA et al. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum. Vaccin. 2(6), 255-260 (2006
123. Durbin AP, Kirkpatrick BD, Pierce KK et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: A randomized, double-blind clinical trial. J. Infect. Dis. 207(6), 957-965 (2013
124. Putnak R, Barvir DA, Burrous JM et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: Immunogenicity and protection in mice and rhesus monkeys. J. Infect. Dis. 174(6), 1176-1184 (1996
125. Putnak R, Cassidy K, Conforti N et al. Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells. Am. J. Trop. Med. Hyg. 55(5), 504-510 (1996
126. Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 29(42), 7267- 7275 (2011
127. Clements DE, Coller BA, Lieberman MM et al. Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys. Vaccine 28(15), 2705-2715 (2010
128. Robert Putnak J, Coller BA, Voss G et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23(35), 4442-4452 (2005
129. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30(Suppl. 5), F123-F138 (2012
130. Pumpens P, Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 44(2-3), 98-114 (2001
131. Arora U, Tyagi P, Swaminathan S, Khanna N. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice. Vaccine 31(6), 873-878 (2013
132. Arora U, Tyagi P, Swaminathan S, Khanna N. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2. J. Nanobiotechnol. 10, 30 (2012
133. Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV. Viral vectors as vaccine platforms: Deployment in sight. Curr. Opin. Immunol. 23(3), 377-382 (2011
134. Khanam S, Pilankatta R, Khanna N, Swaminathan S. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 27(43), 6011-6021 (2009
135. Raviprakash K, Wang D, Ewing D et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J. Virol. 82(14), 6927-6934 (2008
136. White LJ, Sariol CA, Mattocks MD et al. An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection. J. Virol. 87(6), 3409-3424 (2012
137. Danko JR, Beckett CG, Porter KR. Development of dengue DNA vaccines. Vaccine 29(42), 7261-7266 (2011
138. Lu H, Xu XF, Gao N, Fan DY, Wang J, An J. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: Their immunity and protective efficacy in mice. Mol. Immunol. 54(2), 109-114 (2013
139. Beckett CG, Tjaden J, Burgess T et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 29(5), 960-968 (2011
140. Lu S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21(3), 346-351 (2009
141. George JA, Eo SK. Distinct humoral and cellular immunity induced by alternating prime-boost vaccination using plasmid DNA and live viral vector vaccines expressing the E protein of dengue virus type 2. Immune Netw. 11(5), 268-280 (2011
142. Simmons M, Burgess T, Lynch J, Putnak R. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 396(2), 280-288 (2010
143. Crill WD, Hughes HR, Trainor NB, Davis BS, Whitney MT, Chang GJ. Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front. Immunol. 3, 334 (2012
144. DeRoeck D, Deen J, Clemens JD. Policymakers' views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countries. Vaccine 22(1), 121-129 (2003
145. WHO. Guidelines for the clinical evaluation of dengue vaccines in endemic areas. (2008
146. Mahoney RT, Francis DP, Frazatti-Gallina NM et al. Cost of production of live attenuated dengue vaccines: A case study of the Instituto Butantan, Sao Paulo, Brazil. Vaccine 30(32), 4892-4896 (2012
147. Wilder-Smith A, Deen JL. Dengue vaccines for travelers. Expert Rev. Vaccines 7(5), 569-578 (2008
148. WHO. Vaccine introduction guidelines. WHO/IVB/05.18 (2005
149. Durbin AP, Whitehead SS. The dengue human challenge model: Has the time come to accept this challenge? J. Infect. Dis. 207(5), 697-699 (2013